The identification and characterization of a STAT5 gene signature in hematologic malignancies-Reference-Cited by-同舟云学术

The identification and characterization of a STAT5 gene signature in hematologic malignancies

Published:2015-01-01 Issue:1 Volume:15 Page:79-87
ISSN:1875-8592
Container-title:Cancer Biomarkers
language:
Short-container-title:CBM

Author:

Sonkin Dmitriy¹,Palmer Michael²,Rong Xianhui²,Horrigan Kim²,Regnier Catherine H.³,Fanton Christie⁴,Holash Jocelyn⁴,Pinzon-Ortiz Maria²,Squires Matthew⁵,Sirulnik Andres⁵,Radimerski Thomas³,Schlegel Robert²,Morrissey Michael¹,Cao Z. Alexander²

Affiliation:

1. Novartis Institutes for Biomedical Research, Cambridge, MA, USA

2. Novartis Oncology Translational Medicine, Cambridge, MA, USA

3. Novartis Institutes for Biomedical Research, Basel, Switzerland

4. Novartis Institutes for Biomedical Research, Emeryville, CA, USA

5. Novartis Oncology Global Development, Cambridge, MA, USA

Publisher

IOS Press

Subject

Cancer Research,Genetics,Oncology,General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of histone lactylation on the tumor microenvironment and metabolic pathways and its potential in cancer therapy;Genes & Genomics;2024-08-10

2. Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies;Computers in Biology and Medicine;2023-05

3. SOCS2 protects against chemical-induced hepatocellular carcinoma progression by modulating inflammation and cell proliferation in the liver;Biomedicine & Pharmacotherapy;2023-01

4. The membrane-associated ubiquitin ligases MARCH2 and MARCH3 target IL-5 receptor alpha to negatively regulate eosinophilic airway inflammation;Cellular & Molecular Immunology;2022-08-19

5. STAT5 and STAT5 Inhibitors in Hematological Malignancies;Anti-Cancer Agents in Medicinal Chemistry;2020-01-24